NO760745L - - Google Patents

Info

Publication number
NO760745L
NO760745L NO760745A NO760745A NO760745L NO 760745 L NO760745 L NO 760745L NO 760745 A NO760745 A NO 760745A NO 760745 A NO760745 A NO 760745A NO 760745 L NO760745 L NO 760745L
Authority
NO
Norway
Prior art keywords
formula
compounds
carbon atoms
stands
stated
Prior art date
Application number
NO760745A
Other languages
Norwegian (no)
Inventor
A Closse
W Haeflinger
D Hauser
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH312975A external-priority patent/CH614707A5/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO760745L publication Critical patent/NO760745L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

"Fremgangsmåte for fremstilling av nye "Procedure for the production of new

organiske_f orbindelser_." organic_compounds_."

Foreliggende oppfinnelse vedrører en fremgangsmåte for fremstilling av nye organiske forbindelser med formel I The present invention relates to a method for the production of new organic compounds with formula I

hvori R1står for alkyl med 1 til 10 karbonatomer, cykloalkyl med 3 til 8 karbonatomer eller fenyl, R2står for hydrogen eller lavere alkyl og står for halogen, nitro, lavere alkyl, metyltio, hydroksy, lavere alkoksy, acyloksy eller acylamino, idet R^ikke betyr hydrogen når R^ befinner seg i 5-still ingen, og når R^og R2 står for en rettlinjet alkylkjede med 1 til 5 karbonatomer og er idenfeiskå. Det særegne ved fremgangsmåten i henhold til oppfinnelsen er at forbindelser med formel II in which R1 represents alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or phenyl, R2 represents hydrogen or lower alkyl and represents halogen, nitro, lower alkyl, methylthio, hydroxy, lower alkoxy, acyloxy or acylamino, R^ not means hydrogen when R^ is in the 5-still none, and when R^ and R 2 stand for a linear alkyl chain with 1 to 5 carbon atoms and are idenfeiskå. The peculiarity of the method according to the invention is that compounds of formula II

hvori R^, R^ og R^har den ovennevnte betydning, laktoniseres. in which R^, R^ and R^ have the above meaning, are lactonized.

Hvis R. betyr cykloalkyl inneholder denne rest foretrukket 5 til 7 karbonatomer og utgjør spesielt cyklopentyl eller cykloheksyl. Hvis R^ betyr alkyl, så inneholder denne foretrukket 3 til 6, spesielt 3 eller 4,>.karbonatomer og er foretrukket forgrenet og utgjør spesielt isobutyl eller isopropyl. If R. means cycloalkyl, this residue preferably contains 5 to 7 carbon atoms and constitutes in particular cyclopentyl or cyclohexyl. If R 1 means alkyl, then this preferably contains 3 to 6, especially 3 or 4, carbon atoms and is preferably branched and constitutes in particular isobutyl or isopropyl.

Betyr R^lavere alkyl inneholder denne 1 til 4 karbonatomer og utgjør foretrukket metyl. Means R^lower alkyl, this contains 1 to 4 carbon atoms and is preferably methyl.

Substituenten R^betyr foretrukket halogen, dvs. klor, brom eller fluor, og utgjør foretrukket klor. Hvis R^ betyr lavere alkyl eller ibavere alkoksy, inneholder denne foretrukket 1 til 4, f.eks. 2 eller spesielt 1 karbonatom© Hvis R^betyr en acyloksy eller aeyiaminorest, inneholder denne foretrukket 1 til 4, spesielt 2 karbonatomer. Rj. befinner seg foretrukket i 5-stillingen. The substituent R^ preferably means halogen, i.e. chlorine, bromine or fluorine, and preferably constitutes chlorine. If R 1 means lower alkyl or lower alkoxy, this preferably contains 1 to 4, e.g. 2 or in particular 1 carbon atom© If R^ denotes an acyloxy or aeyiamino radical, this preferably contains 1 to 4, in particular 2 carbon atoms. Rj. is preferably located in the 5 position.

Laktoniseringen av forbindelsene med formel II ved fremgangsmåtenThe lactonization of the compounds of formula II by the process

i henhold til oppfinnelsen skjer etter i og for seg kjente metoder, f.eks. som beskrevet i eksempel I. according to the invention takes place according to per se known methods, e.g. as described in Example I.

De som utgangsprodukter anvendte forbindelser med formel II kan erholdes etter i og for seg kjente metoder. På vanlig måte av-leder disse forbindelser seg fra de tilsvarende forbindelser med formel II, hvori R^og R^betyr hydrogen og hvori eventuelt hydroksygruppen i ringskjellettet midlertidig beskyttes med en alkoksygruppe og den fri karboksylgruppe midlertidig med en ester-gruppe. The compounds of formula II used as starting products can be obtained by methods known per se. In the usual way, these compounds are derived from the corresponding compounds of formula II, in which R^ and R^ mean hydrogen and in which, where appropriate, the hydroxy group in the ring skeleton is temporarily protected with an alkoxy group and the free carboxyl group temporarily with an ester group.

Forbindelsene med formel I utmerker seg ved farmakologiske virkninger og kan følgelig anvendes som medisin. Således har forbindelsene med formel I en ødemhemmende og betennelseshemmende virkning. The compounds of formula I are distinguished by their pharmacological effects and can consequently be used as medicine. Thus, the compounds of formula I have an anti-oedema and anti-inflammatory effect.

Videre har forbindelsene med formel I en febersenkende og anal-getisk virkning. Endelig egner de seg som blodplate-aggregasjohs-s hemmere. Furthermore, the compounds of formula I have a fever-reducing and analgesic effect. Finally, they are suitable as platelet aggregation inhibitors.

Som medisin kan forbindelsene med formel I inneholdes sammen med vanlige farmasøytiske hjelpestoffer i medisinske pneparater som f.eks. tabletter, kapsler eller løsninger. Disse medisinske preparater kan fremstilles etter i og for seg kjente metoder. As medicine, the compounds of formula I can be contained together with common pharmaceutical excipients in medical pneparats such as e.g. tablets, capsules or solutions. These medical preparations can be prepared according to methods known per se.

I de etterfølgende eksempler er alle temperaturangivelser i grader celsius og er ukorrigert. In the following examples, all temperature indications are in degrees Celsius and are uncorrected.

Eksempel 1; 5-kloro-6-cykloheksyl-2^Example 1; 5-Chloro-6-cyclohexyl-2^

5 g '3-kloro-4-cykloheksyl-6-hydroksy-feiryleddiksyre løses under oppvarming i toluea, tilsettes 50 mg p-toluensulfonsyre og kokes deretter i 3 timer under vannutskyllér. Den etter avdamping tilbakeblivende olje renses på den 100-dobbelte mengde kiselgel "Merk". Med kloroform lar det ønskede produkt seg eluere og omkrystalliseres fra metylenklorid-petroleter. Krystallene smelter ved 100 - 102°C. 5 g of 3-chloro-4-cyclohexyl-6-hydroxyfeyrylacetic acid are dissolved while heating in toluene, 50 mg of p-toluenesulfonic acid are added and then boiled for 3 hours under a water rinse. The oil remaining after evaporation is purified on the 100-fold amount of silica gel "Mark". With chloroform, the desired product can be eluted and recrystallized from methylene chloride-petroleum ether. The crystals melt at 100 - 102°C.

På analog måte fremstilles de følgende forbindelser med formel I, idet R^, R^ og R^har følgende betydning: In an analogous way, the following compounds of formula I are prepared, where R^, R^ and R^ have the following meanings:

Claims (4)

1.. Nye forbindelser méd formel I 1.. New compounds with formula I hvori R^ står for alkyl:.med 1 til 10 karbonatomer, cykloalkyl med 3 til 8 karbonatomer eller fenyl, R ? står for hydrogen eller lavere alkyl og R^ står for halogen, nitro, lavere alkyl, metyltio, hydroksy, lavere alkoksy, acyloksy eller acylamino, idet R2 ikke betyr hydrogen når R^ befinner seg i 5-stillingen, og når R^ og i R^ står for en rettlinjet alkylkjede med 1 til 5 karbonatomer og er identiske.in which R^ stands for alkyl:.with 1 to 10 carbon atoms, cycloalkyl with 3 to 8 carbon atoms or phenyl, R ? stands for hydrogen or lower alkyl and R^ stands for halogen, nitro, lower alkyl, methylthio, hydroxy, lower alkoxy, acyloxy or acylamino, R2 not meaning hydrogen when R^ is in the 5-position, and when R^ and in R^ represents a linear alkyl chain of 1 to 5 carbon atoms and are identical. 2. Nye forbindelser med formel I som angitt i krav 1, karakterisert ved at R2 betyr lavere alkyl når R^ står for alkyl med 1 til 5 karbonatomer og R^ står for halogen, lavere alkyl eller lavere alkoksy.2. New compounds of formula I as stated in claim 1, characterized in that R2 means lower alkyl when R^ stands for alkyl with 1 to 5 carbon atoms and R^ stands for halogen, lower alkyl or lower alkoxy. 3. Fremgangsmåte for fremstilling av de nye forbindelser med formel I som er angitt i krav 1, hvori R^ , R2 og R^ har den i knav 1 angitte betydning, karakterisert ved at forbindelser med formelII 3. Process for the preparation of the new compounds of formula I which are specified in claim 1, in which R^, R2 and R^ have the meaning specified in clause 1, characterized in that compounds of formula II hvori R^ , R2 ,og R^ har den i krav 1 angitte, betydning, laktoniseres.in which R^ , R 2 , and R^ have the meaning stated in claim 1, lactonized. 4. Fremgangsmåte som angitt i krav 3, for fremstilling av forbindelser hvori R^, R^ og R^ har den i krav 2 angitte betydning, karakterisert ved at forbindelser med formel II, hvori R^ , R^ og R^ har den i krav 2 angitte betydning, laktoniseres.4. Process as stated in claim 3, for the preparation of compounds in which R^, R^ and R^ have the meaning stated in claim 2, characterized in that compounds of formula II, in which R^, R^ and R^ have the i claim 2 stated meaning, is lactonised.
NO760745A 1975-03-12 1976-03-04 NO760745L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH312975A CH614707A5 (en) 1975-03-12 1975-03-12 Process for the preparation of novel dihydrobenzofuranone derivatives
CH967875 1975-07-24

Publications (1)

Publication Number Publication Date
NO760745L true NO760745L (en) 1976-09-14

Family

ID=25692258

Family Applications (1)

Application Number Title Priority Date Filing Date
NO760745A NO760745L (en) 1975-03-12 1976-03-04

Country Status (19)

Country Link
JP (1) JPS51113864A (en)
AT (1) AT357516B (en)
AU (1) AU508681B2 (en)
CA (1) CA1086757A (en)
DD (1) DD125210A5 (en)
DE (1) DE2608697A1 (en)
DK (1) DK137274B (en)
ES (1) ES445922A1 (en)
FI (1) FI760548A (en)
FR (1) FR2303540A1 (en)
GB (1) GB1546701A (en)
IE (1) IE43704B1 (en)
IL (1) IL49192A (en)
NL (1) NL7602393A (en)
NO (1) NO760745L (en)
NZ (1) NZ180273A (en)
PT (1) PT64886B (en)
SE (1) SE7603053L (en)
YU (1) YU63576A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514415A (en) * 1981-10-28 1985-04-30 Ciba Geigy Corporation Benzofuran-2(3H)-ones used as anti-inflammatory agents
US4849428A (en) * 1987-11-23 1989-07-18 The Procter & Gamble Company Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds, compositions and use

Also Published As

Publication number Publication date
DD125210A5 (en) 1977-04-06
DK137274B (en) 1978-02-13
FR2303540A1 (en) 1976-10-08
NL7602393A (en) 1976-09-14
IL49192A (en) 1981-01-30
DK137274C (en) 1978-07-17
IE43704L (en) 1976-09-12
CA1086757A (en) 1980-09-30
AU508681B2 (en) 1980-03-27
AT357516B (en) 1980-07-10
PT64886A (en) 1976-03-31
GB1546701A (en) 1979-05-31
NZ180273A (en) 1978-03-06
ATA173876A (en) 1979-12-15
DE2608697A1 (en) 1976-09-23
DK92176A (en) 1976-09-13
ES445922A1 (en) 1977-08-16
PT64886B (en) 1977-11-17
FR2303540B1 (en) 1979-07-20
SE7603053L (en) 1976-09-13
IE43704B1 (en) 1981-05-06
FI760548A (en) 1976-09-13
IL49192A0 (en) 1976-05-31
YU63576A (en) 1982-05-31
AU1197076A (en) 1977-09-15
JPS51113864A (en) 1976-10-07

Similar Documents

Publication Publication Date Title
US6469043B1 (en) Sulfonamide-containing indole compounds
NO137440B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PLEUROMUTILINES
US4032534A (en) Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids
US2924603A (en) Aralkylbenzmorphan derivatives
US4914099A (en) Hydantoin derivatives as aldose reductase inhibitors
US3428652A (en) Anguidine derivatives
US5010097A (en) Novel compounds
CA2214744C (en) 3-(bis-substituted phenylmethylene)oxindole derivatives
NO760745L (en)
US4330550A (en) Oxoimidazolinealkanoic acids and their salts and esters, their preparation and pharmaceutical compositions containing them
NO764012L (en)
US4297357A (en) N-Phenethylacetamide compounds and process for preparation thereof
NO780576L (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE TRIAZINE DERIVATIVES
US4053621A (en) 1-[2-(βNaphthyloxy)ethyl]-3-methylpyrazolone-(5) and antithrombotic and antithrombolytic compositions and methods utilizing them
AU712378B2 (en) Intimal thickening inhibitory agent
NO813107L (en) PROCEDURE FOR THE PREPARATION OF IMIDAZOLS WITH ANTIDEPRESSIVE ACTIVITY.
US4168312A (en) Quinolone derivatives
NO132307B (en)
NO144632B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE DIANHYDROHEXITID ACYL DERIVATIVES
US3882143A (en) 4-(2-hydroxy-3-aminopropoxy)oxindole derivatives
GB1570328A (en) Thienopyridines
US4139709A (en) 1,2-Diphenyl-3,5-ditrifluoroacetyloxy-4-butyl-5-hydroxy-3-pyrazoline
EP0145304B1 (en) Tetrahydro-beta-carboline derivatives and process for the preparation thereof
NO160141B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED AS-TRIAZINE DERIVATIVES.
US3816411A (en) Thiadiazolyl amino penicillins